Free Trial

Oruka Therapeutics (ORKA) Competitors

Oruka Therapeutics logo
$14.23 -0.31 (-2.13%)
Closing price 04:00 PM Eastern
Extended Trading
$14.24 +0.00 (+0.04%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORKA vs. KNSA, TWST, CNTA, BEAM, CGON, DNLI, HRMY, IRON, MESO, and BLTE

Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), Disc Medicine (IRON), Mesoblast (MESO), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

Oruka Therapeutics vs. Its Competitors

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Kiniksa Pharmaceuticals International has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500.

Oruka Therapeutics has a net margin of 0.00% compared to Kiniksa Pharmaceuticals International's net margin of -3.52%. Kiniksa Pharmaceuticals International's return on equity of -3.83% beat Oruka Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals International-3.52% -3.83% -2.98%
Oruka Therapeutics N/A -25.66%-23.39%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Oruka Therapeutics. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals International$423.24M4.64-$43.19M-$0.25-107.60
Oruka TherapeuticsN/AN/A-$83.72M-$4.51-3.16

Kiniksa Pharmaceuticals International presently has a consensus target price of $39.67, suggesting a potential upside of 47.46%. Oruka Therapeutics has a consensus target price of $40.38, suggesting a potential upside of 183.73%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals International
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oruka Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 11 mentions for Oruka Therapeutics and 8 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.61 beat Oruka Therapeutics' score of 0.27 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals International
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
0 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Kiniksa Pharmaceuticals International beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORKA vs. The Competition

MetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$544.39M$2.48B$5.67B$9.49B
Dividend YieldN/A1.80%4.05%4.00%
P/E RatioN/A9.1127.9419.95
Price / SalesN/A544.41396.5882.68
Price / CashN/A166.9336.1958.45
Price / Book1.315.228.635.82
Net Income-$83.72M$30.99M$3.24B$258.42M
7 Day Performance-7.36%4.29%3.22%1.94%
1 Month Performance21.00%13.40%10.72%12.02%
1 Year PerformanceN/A0.59%34.94%20.80%

Oruka Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORKA
Oruka Therapeutics
2.7729 of 5 stars
$14.23
-2.1%
$40.38
+183.7%
N/A$544.39MN/A0.00N/ANews Coverage
Upcoming Earnings
Analyst Forecast
KNSA
Kiniksa Pharmaceuticals International
3.4797 of 5 stars
$28.42
-2.1%
$39.67
+39.6%
+3.2%$2.12B$423.24M-113.68220News Coverage
Positive News
Analyst Forecast
TWST
Twist Bioscience
4.3598 of 5 stars
$34.77
-1.1%
$50.40
+45.0%
-38.8%$2.11B$312.97M-10.70990Positive News
CNTA
Centessa Pharmaceuticals
3.3282 of 5 stars
$16.06
+2.4%
$28.10
+75.0%
+57.8%$2.10B$6.85M-8.87200Analyst Forecast
Insider Trade
BEAM
Beam Therapeutics
2.2934 of 5 stars
$21.03
+1.3%
$48.75
+131.8%
-26.9%$2.09B$63.52M-4.56510Analyst Upgrade
Analyst Revision
CGON
CG Oncology
2.5116 of 5 stars
$26.90
+0.6%
$55.30
+105.6%
-23.3%$2.04B$1.14M-17.8161
DNLI
Denali Therapeutics
4.1936 of 5 stars
$13.83
-1.2%
$33.71
+143.8%
-39.4%$2.03BN/A-5.18430Upcoming Earnings
HRMY
Harmony Biosciences
4.8366 of 5 stars
$35.25
+0.1%
$51.00
+44.7%
+11.1%$2.02B$714.73M13.45200Positive News
Analyst Forecast
Analyst Revision
IRON
Disc Medicine
3.3742 of 5 stars
$59.38
+2.8%
$95.73
+61.2%
+32.1%$2.00BN/A-15.1530Analyst Forecast
MESO
Mesoblast
0.9153 of 5 stars
$14.65
-6.2%
$18.00
+22.9%
+94.6%$2.00B$5.67M0.0080Upcoming Earnings
Gap Up
BLTE
Belite Bio
1.7601 of 5 stars
$61.30
+0.6%
$96.67
+57.7%
+24.4%$1.94BN/A-45.0710

Related Companies and Tools


This page (NASDAQ:ORKA) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners